bluebird bio, Inc.
DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES

Last updated:

Abstract:

The present disclosure provides improved compositions for adoptive T cell therapies targeting CD33 for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. The present disclosure also relates to adoptive T cell therapies targeting CD33 and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Status:
Application
Type:

Utility

Filling date:

13 Dec 2019

Issue date:

27 Jan 2022